Ultragenyx Pharmaceutical Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $673.0M | $560.0M | $434.0M | $363.3M | $351.4M |
| Selling, general & administrative | $349.0M | $321.0M | $310.0M | $278.1M | $220.0M |
| Research and development | $750.0M | $698.0M | $648.0M | $705.8M | $497.2M |
| Operating income | -$535.0M | -$536.0M | -$569.0M | -$648.9M | -$381.7M |
| Pretax income | -$571.0M | -$567.0M | -$609.0M | -$701.7M | -$453.0M |
| Income tax expense | $4.0M | $2.0M | -$2.0M | $5.7M | $1.0M |
| Net income | -$575.0M | -$569.0M | -$607.0M | -$707.4M | -$454.0M |
| Balance Sheet | |||||
| Cash and equivalents | $421.0M | $174.0M | $214.0M | $132.9M | $307.6M |
| Current assets | $951.0M | $817.0M | $732.2M | $883.9M | $856.6M |
| Total assets | $1.5B | $1.5B | $1.5B | $1.5B | $1.5B |
| Current liabilities | $384.0M | $344.0M | $280.4M | $261.2M | $181.4M |
| Total liabilities | $1.6B | $1.2B | $1.2B | $1.2B | $599.8M |
| Stockholders' equity | -$80.0M | $255.0M | $275.0M | $352.0M | $922.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$466.0M | -$414.0M | -$475.0M | -$380.5M | -$338.7M |
| Depreciation and amortization | $35.0M | $36.0M | $26.0M | $18.2M | $13.2M |
| Stock-based compensation | $153.0M | $158.0M | $135.0M | $130.4M | $105.0M |
| Capital expenditure | $6.0M | $7.0M | $44.0M | $116.1M | $73.1M |
| Free cash flow | -$472.0M | -$421.0M | -$519.0M | -$496.6M | -$411.8M |
Shares outstanding 98.5M · Free float 91.9%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.